leisure time -WSS

leisure time

author：knowledge 2025-09-27 13:09:57 - browse：63

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

hotspot

WSS

FDA authorizes Novavax’s updated Covid

Bristol 'take

Sana to lay off nearly a third of staff, de

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Senate panel eyes new effort on drug shortages

3 questions for the future of Biden's cancer moonshot

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Hollywood unions extend contract negotiations for actors

VC firm General Catalyst wants to buy a health system

As demand for Covid shots wanes, Moderna seeks its next success

Bird flu in milk supply is likely coming from asymptomatic cows

How one medical school became remarkably diverse

FDA panel signals lack of confidence in Amgen cancer drug data

Alkermes shareholders re

Chemotherapy drug shortage eases slightly but still widespread

Sports medicine is finally prioritizing gender equality

Physician executives need more than on

leisure time

FDA panel signals lack of confidence in Amgen cancer drug data

Dogs on Prozac: What pet anti

UnitedHealth financials solid despite Change Healthcare cyberattack

Orangutan used medicinal plant to treat wound, first time ever seen

Cell therapy fails to slow type 1 diabetes, but safety is established

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Wikipedia

entertainment

hotspot

focus